Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

C4 Therapeutics stock

CCCC
US12529R1077

Price

1.62
Today +/-
+0.06
Today %
+4.43 %

C4 Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the C4 Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the C4 Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the C4 Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze C4 Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

C4 Therapeutics Stock Price History

DateC4 Therapeutics Price
4/28/20251.62 undefined
4/25/20251.55 undefined
4/25/20251.52 undefined
4/24/20251.63 undefined
4/23/20251.63 undefined
4/22/20251.55 undefined
4/21/20251.42 undefined
4/17/20251.26 undefined
4/17/20251.24 undefined
4/16/20251.11 undefined
4/15/20251.22 undefined
4/14/20251.22 undefined
4/11/20251.21 undefined
4/11/20251.22 undefined
4/10/20251.23 undefined
4/9/20251.34 undefined
4/8/20251.26 undefined
4/7/20251.35 undefined
4/4/20251.32 undefined
4/3/20251.40 undefined
4/2/20251.51 undefined
4/1/20251.45 undefined
3/31/20251.62 undefined

C4 Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into C4 Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by C4 Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects C4 Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of C4 Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into C4 Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing C4 Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on C4 Therapeutics’s growth potential.

C4 Therapeutics Revenue, EBIT and net profit per share

DateC4 Therapeutics RevenueC4 Therapeutics EBITC4 Therapeutics Net Income
2030e8.85 B undefined0 undefined5.27 B undefined
2029e2.1 B undefined534.04 M undefined1.61 B undefined
2028e210.96 M undefined-62.44 M undefined141.92 M undefined
2027e19.86 M undefined-192.79 M undefined-108.61 M undefined
2026e33.62 M undefined-154.36 M undefined-121.17 M undefined
2025e24.66 M undefined-147.2 M undefined-134.2 M undefined
202435.58 M undefined-117.18 M undefined-105.32 M undefined
202320.76 M undefined-139.03 M undefined-132.49 M undefined
202231.1 M undefined-129.53 M undefined-128.18 M undefined
202145.79 M undefined-82.13 M undefined-83.89 M undefined
202033.2 M undefined-60.45 M undefined-66.34 M undefined
201921.38 M undefined-35.45 M undefined-42.57 M undefined
201819.36 M undefined-16.39 M undefined-24.11 M undefined

C4 Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20182019202020212022202320242025e2026e2027e2028e2029e2030e
0.020.020.030.050.030.020.040.020.030.020.212.18.85
-10.5357.1436.36-31.11-35.4875.00-31.4337.50-42.421,005.26899.52321.82
-------------
0000000000000
-0.02-0.04-0.07-0.08-0.13-0.13-0.11-0.13-0.12-0.110.141.615.27
-75.0057.1425.7654.223.13-20.4527.62-9.70-10.74-230.561,040.43227.86
41.5541.5543.0646.0448.8649.6469.37000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The C4 Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the C4 Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (k)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2018201920202021202220232024
             
36.390.5371.7309.3276.2253.68244.9
86.44.64.55.71.511.83.1
0000000
0000000
0.81.64.810.79.95.719.76
123.596.7381325.7287.6271.19257.77
20.418.916.635.177.571.0963.38
000142.26128.0122.36
0000000
0000000
0000000
2.62.62.63.84.86.176.1
2321.519.2181.1143.3105.2691.84
146.5118.2400.2506.8430.9376.45349.6
             
1111110000.010.01
3.65.5464.6658.1689.3774.62849.63
-83.4-117.5-183.8-267.7-395.9-528.38-633.7
000-800-4,100-12753
0000000
31.2-1280.8389.6289.3246.11215.99
1.25.45.74.51.21.451.33
3.37.310.114.522.423.8123.27
19.52128.132.218.717.5120.58
0000000
00002.300
2433.743.951.244.642.7745.18
0010.110.89.200
0000000
91.385.665.455.187.987.5788.44
91.385.675.565.997.187.5788.44
115.3119.3119.4117.1141.7130.34133.62
146.5118.3400.2506.7431376.45349.6
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of C4 Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand C4 Therapeutics's financial health and stability.

Assets

C4 Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that C4 Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of C4 Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into C4 Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (k)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (k)
PAID TAXES (k)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201820192020202120222023
-15-34-66-83-128-132
1,0001,0001,0001,0001,0001,000
000000
-584-13-30-16-6
3414476757
0001,0001,0000
000001,000
-1655-67-86-105-106
-2-10-1-5-1
36-1-190-18958158
390-189-18863160
000000
001100-12
103362057
10348171145
00016900
000000
215491-104-4697
-19.6754.26-67.9-88.25-111.44-108.55
000000

C4 Therapeutics stock margins

The C4 Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of C4 Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for C4 Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the C4 Therapeutics's sales revenue. A higher gross margin percentage indicates that the C4 Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the C4 Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the C4 Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the C4 Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the C4 Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the C4 Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

C4 Therapeutics Margin History

C4 Therapeutics Gross marginC4 Therapeutics Profit marginC4 Therapeutics EBIT marginC4 Therapeutics Profit margin
2030e0 %0 %59.55 %
2029e0 %25.44 %76.65 %
2028e0 %-29.6 %67.27 %
2027e0 %-970.95 %-547.01 %
2026e0 %-459.13 %-360.4 %
2025e0 %-596.83 %-544.11 %
20240 %-329.3 %-295.96 %
20230 %-669.84 %-638.34 %
20220 %-416.5 %-412.15 %
20210 %-179.36 %-183.21 %
20200 %-182.08 %-199.82 %
20190 %-165.81 %-199.11 %
20180 %-84.66 %-124.54 %

C4 Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The C4 Therapeutics earnings per share therefore indicates how much revenue C4 Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue C4 Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates C4 Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of C4 Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating C4 Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

C4 Therapeutics Revenue, EBIT and net profit per share

DateC4 Therapeutics Sales per ShareC4 Therapeutics EBIT per shareC4 Therapeutics Earnings per Share
2030e124.72 undefined0 undefined74.28 undefined
2029e29.57 undefined0 undefined22.66 undefined
2028e2.97 undefined0 undefined2 undefined
2027e0.28 undefined0 undefined-1.53 undefined
2026e0.47 undefined0 undefined-1.71 undefined
2025e0.35 undefined0 undefined-1.89 undefined
20240.51 undefined-1.69 undefined-1.52 undefined
20230.42 undefined-2.8 undefined-2.67 undefined
20220.64 undefined-2.65 undefined-2.62 undefined
20210.99 undefined-1.78 undefined-1.82 undefined
20200.77 undefined-1.4 undefined-1.54 undefined
20190.51 undefined-0.85 undefined-1.02 undefined
20180.47 undefined-0.39 undefined-0.58 undefined

C4 Therapeutics business model

The company C4 Therapeutics Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts. The company specializes in the development of drugs that work based on targeted protein degradation. This approach aims to specifically break down proteins in the body that are associated with various diseases. C4 Therapeutics develops special molecules that bind to these proteins and help break them down. The company's business model is based on collaboration with other companies in the pharmaceutical industry, where they develop drug candidates and license them to other companies for further development and marketing. C4 Therapeutics has a specialized strategy to become a leader in the field of targeted protein degradation. They are currently active in various areas, including the development of cancer drugs with a focus on proteins responsible for tumor growth, as well as neurology drugs for diseases like Alzheimer's and Parkinson's. Their important development is the PROTAC platform technology, which allows targeted protein degradation by binding two different molecules to the protein, triggering a cascade of reactions that lead to protein breakdown. Overall, C4 Therapeutics is an innovative and dynamic company specializing in drug development based on targeted protein degradation, with promising potential to treat a range of diseases. Despite being relatively young, the company has already achieved numerous successes and is expected to play an important role in the pharmaceutical industry in the future. C4 Therapeutics is one of the most popular companies on Eulerpool.com.

C4 Therapeutics SWOT Analysis

Strengths

C4 Therapeutics Inc has several strengths that contribute to its success in the market. One of its key strengths is its innovative approach to developing targeted protein degradation therapeutics. This unique strategy sets the company apart from its competitors and provides a competitive advantage in the industry. Additionally, C4 Therapeutics has a strong and experienced management team that brings expertise in drug discovery and development.

Weaknesses

Despite its strengths, C4 Therapeutics Inc also faces certain weaknesses that need to be addressed. One weakness is the company's limited product pipeline. While its targeted protein degradation platform shows promise, the absence of a diversified portfolio puts the company at risk of relying heavily on a single product or technology. Furthermore, C4 Therapeutics faces challenges in scaling up its manufacturing capabilities to meet potential market demand.

Opportunities

The market presents several opportunities for C4 Therapeutics Inc to capitalize on. Firstly, the growing demand for novel therapeutics and targeted drug delivery systems creates a favorable environment for the company's innovative approach. Additionally, C4 Therapeutics can explore strategic partnerships and collaborations with pharmaceutical companies to enhance its product development capabilities and accelerate the commercialization of its therapies. Furthermore, expanding into new geographic markets can also open up additional revenue streams for the company.

Threats

C4 Therapeutics Inc faces certain threats that could impact its business operations. One major threat is the intense competition within the biopharmaceutical industry. The presence of established players with extensive resources and expertise poses challenges for a relatively small company like C4 Therapeutics. Moreover, regulatory and compliance requirements can pose obstacles to the successful development and commercialization of its products. Additionally, market volatility and economic uncertainties can impact the funding and investment landscape for the company.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

C4 Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

C4 Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

C4 Therapeutics shares outstanding

The number of shares was C4 Therapeutics in 2024 — This indicates how many shares 69.373 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue C4 Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates C4 Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of C4 Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating C4 Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for C4 Therapeutics.

C4 Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2024-0.49 -0.49  (-0.55 %)2024 Q4
9/30/2024-0.39 -0.35  (9.7 %)2024 Q3
6/30/2024-0.38 -0.26  (31.42 %)2024 Q2
3/31/2024-0.36 -0.41  (-14.37 %)2024 Q1
12/31/2023-0.7 -0.7  (-0.55 %)2023 Q4
9/30/2023-0.67 -0.52  (22.76 %)2023 Q3
6/30/2023-0.7 -0.73  (-4.06 %)2023 Q2
3/31/2023-0.76 -0.71  (6.65 %)2023 Q1
12/31/2022-0.76 -0.77  (-1.5 %)2022 Q4
9/30/2022-0.68 -0.65  (4.89 %)2022 Q3
1
2

Eulerpool ESG Scorecard© for the C4 Therapeutics stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

56

👫 Social

80

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees55
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

C4 Therapeutics shareholders

%
Name
Stocks
Change
Date
9.83088 % Soleus Capital Management, L.P.6,978,942374,94612/31/2024
9.65311 % Lynx1 Capital Advisors LLC6,852,744-27,78312/31/2024
8.55416 % Wasatch Global Investors Inc6,072,601395,23312/31/2024
7.84326 % Betta investment Hong Kong Ltd5,567,9285,567,9281/4/2024
6.87521 % BlackRock Institutional Trust Company, N.A.4,880,710606,62012/31/2024
6.87139 % RA Capital Management, LP4,878,000012/31/2024
6.16692 % OrbiMed Advisors, LLC4,377,900012/31/2024
4.71330 % The Vanguard Group, Inc.3,345,973-24,70812/31/2024
4.60588 % Morgan Stanley & Co. LLC3,269,7131,744,49912/31/2024
4.25336 % Samlyn Capital, LLC3,019,4583,019,45812/31/2024
1
2
3
4
5
...
10

C4 Therapeutics Executives and Management Board

Dr. Scott Boyle

(46)
C4 Therapeutics Chief Business Officer
Compensation 3.91 M

Mr. Andrew Hirsch

(53)
C4 Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 3.79 M

Ms. Jolie Siegel

(48)
C4 Therapeutics Chief Legal Officer, Corporate Secretary
Compensation 3.38 M

Mr. Leonard Reyno

(62)
C4 Therapeutics Chief Medical Officer
Compensation 1.67 M

Mr. Utpal Koppikar

(53)
C4 Therapeutics Independent Director
Compensation 126,409
1
2
3
4

C4 Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Roche Holding Stock
Roche Holding
SupplierCustomer0,660,91-0,63-0,15-0,32
Bio-Techne Stock
Bio-Techne
SupplierCustomer0,410,780,760,740,88
Biogen Stock
Biogen
SupplierCustomer0,160,600,240,730,73
Alphabet A Stock
Alphabet A
SupplierCustomer-0,260,870,290,660,23
1

Most common questions regarding C4 Therapeutics

What values and corporate philosophy does C4 Therapeutics represent?

C4 Therapeutics Inc represents strong values and a clear corporate philosophy. As a leading biotechnology company, C4 Therapeutics is dedicated to developing targeted protein degradation (TPD) therapies to treat a wide range of diseases. The company believes in the transformative potential of its TPD platform, which selectively and efficiently eliminates disease-causing proteins. C4 Therapeutics values innovation, scientific excellence, and a patient-centric approach in its pursuit of novel therapies. With a commitment to improving patient outcomes, C4 Therapeutics strives to deliver innovative solutions that address unmet medical needs and bring new hope to patients worldwide.

In which countries and regions is C4 Therapeutics primarily present?

C4 Therapeutics Inc is primarily present in the United States.

What significant milestones has the company C4 Therapeutics achieved?

C4 Therapeutics Inc has achieved several significant milestones. In the past few years, the company has successfully secured multiple partnerships and collaborations with renowned pharmaceutical companies, facilitating the development of innovative therapeutics. Additionally, C4 Therapeutics Inc has demonstrated promising results in preclinical studies, showcasing the therapeutic potential of their targeted protein degradation platform. The company has also successfully raised substantial funding through public offerings, enabling them to advance their research and development efforts. These achievements highlight C4 Therapeutics Inc's dedication to revolutionizing drug discovery and development through their cutting-edge technologies and strategic collaborations.

What is the history and background of the company C4 Therapeutics?

C4 Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Established in 2015, the company combines expertise in targeted protein degradation with innovative small molecule drug discovery to address unmet medical needs. C4T's proprietary Degronimid platform enables the selective elimination of disease-causing proteins, providing a potential breakthrough approach in oncology and other diseases. Through strategic partnerships and collaborations, C4 Therapeutics is advancing its pipeline of drug candidates towards clinical development. With a strong commitment to scientific excellence, C4 Therapeutics aims to revolutionize cancer treatment options and improve patient outcomes.

Who are the main competitors of C4 Therapeutics in the market?

The main competitors of C4 Therapeutics Inc in the market are other companies operating in the field of targeted protein degradation, such as Arvinas Inc, Kymera Therapeutics, Nurix Therapeutics, and PROLynx LLC. These companies are also focused on developing novel therapies that harness the body's natural protein disposal system to selectively eliminate disease-causing proteins. However, C4 Therapeutics Inc aims to differentiate itself through its unique Targeted Protein Degradation (TPD) platform and proprietary small molecule drugs, making it a key player in this competitive market.

In which industries is C4 Therapeutics primarily active?

C4 Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of C4 Therapeutics?

The business model of C4 Therapeutics Inc revolves around targeted protein degradation. By leveraging their proprietary technology, they aim to develop small molecule drugs that can selectively eliminate disease-causing proteins. Their approach offers a potential breakthrough in addressing a wide range of diseases including cancer, neurodegenerative disorders, and autoimmune conditions. C4 Therapeutics focuses on developing drug candidates known as DegronimidTM molecules, which could provide a more precise and efficient way of degrading proteins compared to traditional methods. Through their innovative research and development efforts, C4 Therapeutics Inc aims to bring transformative therapies to patients in need.

What is the P/E ratio of C4 Therapeutics 2025?

The C4 Therapeutics P/E ratio is -0.84.

What is the P/S ratio of C4 Therapeutics 2025?

The C4 Therapeutics P/S ratio is 4.54.

What is the Quality Investing of C4 Therapeutics?

The Quality Investing for C4 Therapeutics is 2/10.

What is the revenue of C4 Therapeutics 2025?

The expected C4 Therapeutics revenue is 24.66 M USD.

How high is the profit of C4 Therapeutics 2025?

The expected C4 Therapeutics profit is -134.2 M USD.

What is the business model of C4 Therapeutics

C4 Therapeutics Inc. is a biopharmaceutical company that focuses on the development of Targeted Protein Degradation (TPD) therapeutics. The company was founded in 2015 in Massachusetts, USA, and has since been focused on developing drugs that target the elimination of abnormal disease-causing proteins. C4 Therapeutics' business model is based on the combination of artificial intelligence (AI) and TPD technology. The company develops molecules that can specifically degrade proteins in diseased cells that pose a threat to health. These molecules are designed to recognize and bind to disease-causing proteins. Once the artificially created molecule binds to the protein, it is disposed of by the cell. The target diseases for C4 are cancer, as well as immune, nervous, and metabolic system diseases. The company has two business areas: Therapeutics and Platforms. In the Therapeutics area, C4 Therapeutics specifically develops drugs to treat cancer and various other diseases. The company already has a product in the clinical phase that is being used to treat patients with advanced stages of cancer. C4T-412 is a molecule designed to eliminate the protein FUBP1, which is overexpressed in many types of cancer and promotes tumor cell growth. In the Platforms area, C4 Therapeutics offers its customers custom services and products that utilize TPD technology. The company has a data platform that allows customers to systematically identify disease proteins. Using artificial intelligence, the precise structure of the disease-causing protein and the appropriate molecules capable of degrading the protein are identified. C4 Therapeutics also offers drug development tools that allow customers to develop their own TPD therapeutics. C4 Therapeutics has formed partnerships with industry leaders such as Roche, Calico, and Novartis. These partnerships facilitate knowledge transfer and often involve collaborative research and development. The company has also formed partnerships with contract research organizations, which allow C4 to expand its development and manufacturing capabilities. The company has a broad intellectual property base and has already received several patents related to its technology and products. C4 Therapeutics has raised over $200 million in venture capital to support the development of its TPD therapeutics and the expansion of its business. In summary, C4 Therapeutics pursues an innovative business model based on the combination of artificial intelligence and TPD technology. The company aims to provide tailored solutions for the treatment of various diseases and has already made progress in the development of TPD therapeutics. With its partnerships and broad intellectual property base, C4 Therapeutics is well positioned to continue growing and expanding in the future.

What is the C4 Therapeutics dividend?

C4 Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does C4 Therapeutics pay dividends?

The dividend cannot currently be calculated for C4 Therapeutics or the company does not pay out a dividend.

What is the C4 Therapeutics ISIN?

The ISIN of C4 Therapeutics is US12529R1077.

What is the C4 Therapeutics ticker?

The ticker of C4 Therapeutics is CCCC.

How much dividend does C4 Therapeutics pay?

Over the past 12 months, C4 Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, C4 Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of C4 Therapeutics?

The current dividend yield of C4 Therapeutics is .

When does C4 Therapeutics pay dividends?

C4 Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of C4 Therapeutics?

C4 Therapeutics paid dividends every year for the past 0 years.

What is the dividend of C4 Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is C4 Therapeutics located?

C4 Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von C4 Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of C4 Therapeutics from 4/29/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/29/2025.

When did C4 Therapeutics pay the last dividend?

The last dividend was paid out on 4/29/2025.

What was the dividend of C4 Therapeutics in the year 2024?

In the year 2024, C4 Therapeutics distributed 0 USD as dividends.

In which currency does C4 Therapeutics pay out the dividend?

The dividends of C4 Therapeutics are distributed in USD.

All fundamentals about C4 Therapeutics

Our stock analysis for C4 Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of C4 Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.